Ultragenyx Pharmaceutical Inc (RARE) concluded trading on Thursday at a closing price of $31.03, with 12.98 million shares of worth about $402.74 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -27.25% during that period and on July 10, 2025 the price saw a loss of about -25.11%. Currently the company’s common shares owned by public are about 93.74M shares, out of which, 88.38M shares are available for trading.
Stock saw a price change of -21.35% in past 5 days and over the past one month there was a price change of -16.21%. Year-to-date (YTD), RARE shares are showing a performance of -25.20% which decreased to -26.23% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $29.59 but also hit the highest price of $60.37 during that period. The average intraday trading volume for Ultragenyx Pharmaceutical Inc shares is 1.27 million. The stock is currently trading -17.36% below its 20-day simple moving average (SMA20), while that difference is down -15.57% for SMA50 and it goes to -27.57% lower than SMA200.
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) currently have 93.74M outstanding shares and institutions hold larger chunk of about 95.29% of that.
The stock has a current market capitalization of $2.93B and its 3Y-monthly beta is at 0.26. It has posted earnings per share of -$5.88 in the same period. It has Quick Ratio of 2.24 while making debt-to-equity ratio of 6.17. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for RARE, volatility over the week remained 5.75% while standing at 4.78% over the month.
Stock’s fiscal year EPS is expected to rise by 18.09% while it is estimated to increase by 32.75% in next year. EPS is likely to grow at an annualized rate of 62.33% for next 5-years, compared to annual growth of 2.45% made by the stock over the past 5-years.
Coverage by Goldman stated Ultragenyx Pharmaceutical Inc (RARE) stock as a Buy in their note to investors on June 06, 2024, suggesting a price target of $67 for the stock. On April 22, 2024, RBC Capital Mkts Initiated their recommendations, while on December 08, 2023, Wells Fargo Initiated their ratings for the stock with a price target of $72. Stock get an Outperform rating from Credit Suisse on June 14, 2023.
